Top

Published in:

01-04-2008 | Case Report

Successful autologous peripheral blood stem cell transplantation in a Jehovah’s Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products

Authors: S. Schmitt, V. Mailaender, G. Egerer, A. Leo, S. Becker, P. Reinhardt, M. Wiesneth, H. Schrezenmeier, A. D. Ho, H. Goldschmidt, T. M. Moehler

Published in: International Journal of Hematology | Issue 3/2008

Abstract

We present a case report of a successful high-dose melphalan therapy and autologous stem cell transplantation without the use of allogeneic blood product support in a 70-year-old patient suffering from multiple myeloma. Based on the experience in this case and thorough evaluation of the literature, we consider pre-transplant Hb level of 11–12 g/dl, platelet count higher than 70/nl, good WHO performance status of two and lower and informed consent as important eligibility criteria. During cytopenia recommended supportive measures include growth factor support with erythropoietin and G-CSF, p.o. iron treatment as well as prophylactic use of anti-fibrinloytic agents. Furthermore we discuss additional options that might be considered depending on the individual factors as e.g. pre-transplant collection and cryoconservation of autologous platelet concentrates. Moreover, an analysis of socio-economic issues regarding this procedure is presented. We conclude that allogeneic blood product free transplantation is a feasible procedure that can be offered to the patients belonging to distinct religious groups refusing allogeneic blood products as Jehova´s Witnesses and patients presenting other contraindications for transfusions.

Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91–7.PubMedCrossRef

Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Engenhart R, Wannenmacher M, et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol. 1997;8(3):243–6.PubMedCrossRef

Goldschmidt H, Haas R, Hegenbart U, Wallmeier M, Egerer G, Moos M, et al. Hochdosischemotherapie beim multiplen myelom. Der Onkologe. 1996;2(Suppl. 1/96):6–12.

Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood. 1998;91(9):3509–17.PubMed

Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah’s witnesses. Transfusion. 1994;34(5):396–401.PubMedCrossRef

Ballen KK, Ford PA, Waitkus H, Emmons RV, Levy W, Doyle P, et al Successful autologous bone marrow transplant without the use of blood product support. Bone Marrow Transplant. 2000;26(2):227–9.PubMedCrossRef

Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol. 2004;22(20):4087–94.PubMedCrossRef

Tenenbaum T, Hasan C, Kramm CM, Janssen G, Laws HJ, Wessalowski R, et al. Oncological management of pediatric cancer patients belonging to Jehovah’s Witnesses: a two-institutional experience report. Onkologie. 2004;27(2):131–7.PubMedCrossRef

Pierelli L, Scambia G, Menichella G, d’Onofrio G, Salerno G, Panici PB, et al. The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. Br J Haematol. 1996;92(2):287–94.PubMedCrossRef

10.

Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43(2):258–70.PubMedCrossRef

11.

Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res. 2001;7(9):2675–81.PubMed

12.

Mesters RM, Padro T, Steins M, Bieker R, Retzlaff S, Kessler T, et al. [Angiogenesis in patients with hematologic malignancies]. Onkologie. 2001;24(Suppl 5):75–80.PubMedCrossRef

13.

Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol. 2004;125(2):149–55.PubMedCrossRef

14.

Sugawa C, Steffes CP, Nakamura R, Sferra JJ, Sferra CS, Sugimura Y, et al. Upper GI bleeding in an urban hospital. Etiology, recurrence, and prognosis. Ann Surg. 1990;212(4):521–6.PubMedCrossRef

15.

Yavorski RT, Wong RK, Maydonovitch C, Battin LS, Furnia A, Amundson DE. Analysis of 3,294 cases of upper gastrointestinal bleeding in military medical facilities. Am J Gastroenterol. 1995;90(4):568–73.PubMed

16.

Burgstaler EA. Blood component collection by apheresis. J Clin Apher. 2006;21(2):142–51.PubMedCrossRef

17.

Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A, et al. Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998;91(10):3601–6.PubMed

18.

Wandt H, Ehninger G, Gallmeier WM. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist. 2001;6(5):446–50.PubMedCrossRef

19.

Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37(4):387–92.PubMedCrossRef

20.

Djerassi I, Farber S, Roy A, Cavins J. Preparation and in vivo circulation of human platelets preserved with combined dimethylsulfoxide and dextrose. Transfusion. 1966;6(6):572–76.PubMedCrossRef

21.

Raymond SL, Pert JH, Dodds WJ. Evaluation of platelet cryopreservation techniques by isolated kidney perfusion. Transfusion. 1975;15(3):219–25.PubMedCrossRef

22.

Schiffer CA, Aisner J, Wiernik PH. Frozen autologous platelet transfusion for patients with leukemia. N Engl J Med. 1978;299(1):7–12.PubMedCrossRef

23.

Wolkers WF, Walker NJ, Tablin F, Crowe JH. Human platelets loaded with trehalose survive freeze-drying. Cryobiology. 2001;42(2):79–87.PubMedCrossRef

24.

Holme S, Sawyer S, Heaton A, Sweeney JD. Studies on platelets exposed to or stored at temperatures below 20 degrees C or above 24 degrees C. Transfusion. 1997;37(1):5–11.PubMedCrossRef

25.

Wiesneth M, Koerner K, Funke I, Seifried E, Cardoso M, Heimpel H, et al. Cryopreserved autologous platelet transfusions in alloimmunized patients with acute leukemia. Beitr Infusionsther. 1992;30:297–300.PubMed

26.

Vadhan-Raj S, Currie LM, Bueso-Ramos C, Livesey SA, Connor J. Enhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietin-treated patients following long-term cryopreservation with a platelet-preserving solution (ThromboSol) and 2% DMSO. Br J Haematol. 1999;104(2):403–11.PubMedCrossRef

27.

Xiao H, Harvey K, Labarrere CA, Kovacs R. Platelet cryopreservation using a combination of epinephrine and dimethyl sulfoxide as cryoprotectants. Cryobiology. 2000;41(2):97–105.PubMedCrossRef

28.

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer. 2006;107(1):136–40.PubMedCrossRef

29.

Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. J Bone Joint Surg Br. 1996;78(3):434–40.PubMed

30.

Andres E, Kurtz JE, Martin-Hunyadi C, Kaltenbach G, Alt M, Weber JC, et al. Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor. Am J Med. 2002;112(6):460–64.PubMedCrossRef

31.

Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood. 2002;99(12):4370–8.PubMedCrossRef

32.

Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15):2433–3.PubMedCrossRef

33.

Olivieri A, Scortechini I, Capelli D, Montanari M, Lucesole M, Gini G, et al. Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplant. 2004;34(8):693–702.PubMedCrossRef

Title: Successful autologous peripheral blood stem cell transplantation in a Jehovah’s Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products
Authors: S. Schmitt
V. Mailaender
G. Egerer
A. Leo
S. Becker
P. Reinhardt
M. Wiesneth
H. Schrezenmeier
A. D. Ho
H. Goldschmidt
T. M. Moehler
Publication date: 01-04-2008
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 3/2008
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-008-0055-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF

A case of adult Langerhans cell histiocytosis showing successfully regenerated osseous tissue of the skull after chemotherapy

Differential expression of HOX genes upon activation of leukocyte sub-populations

Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells

Identification of genes potentially involved in supporting hematopoietic stem cell activity of stromal cell line MC3T3-G2/PA6

The evaluation of hTERT mRNA expression in acute leukemia children and 2 years follow-up of 40 cases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer